Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children

Renal Failure 2026 Open access

Read full text
Authors: Ying Liang, X U Yue, Z P Chen, Zhang Jiali, Hejia Zhang, Lei Lei, L Chen, Mi Lan, Yiming Zhao, C Jia, Zhou Nan
DOI: 10.1080/0886022x.2026.2664988
Cited by: 1
References: 8

Abstract

This study retrospectively evaluated telitacicept in ten pediatric IgA nephropathy patients with proteinuria (24-hour urinary protein: 23.97 ± 26.63 mg/kg). All patients received steroid therapy, and half received combined immunosuppressants. After a median follow-up of 3.75 months, eight patients achieved proteinuria remission (four complete, four partial). Steroid reduction (33.3-92%) occurred in six patients, and four discontinued steroids entirely. Key clinical outcomes included improvements in protein excretion. Adverse events were mild, including injection-site reactions (2 cases), upper respiratory infection (1 case), rash (1 case), and leukopenia (1 case), with no severe events reported. Telitacicept appears effective and safe for reducing proteinuria and steroid use in pediatric IgAN.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Renal Failure
Publisher
Informa UK Limited
Volume
48
Issue
1
Pages
2664988–2664988
Publication date
15 June 2026
Language
EN